Cargando…
Diagnostic criteria, specific mutations, and genetic predisposition in gastrointestinal stromal tumors
In 1998, gastrointestinal stromal tumor (GIST) emerged as a distinct oncogenetic entity and subsequently became a paradigm of targeted therapies in solid tumors. Diagnosis of GIST relies on both histology and immunohistochemistry. Ninety-five percent of GISTs express either KIT or DOG-1. Approximate...
Autores principales: | Bachet, Jean-Baptiste, Emile, Jean-François |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681166/ https://www.ncbi.nlm.nih.gov/pubmed/23776354 http://dx.doi.org/10.2147/TACG.S7191 |
Ejemplares similares
-
Copy-neutral loss of heterozygosity and chromosome gains and losses are frequent in gastrointestinal stromal tumors
por: Lourenço, Nelson, et al.
Publicado: (2014) -
Update on Molecular Genetics of Gastrointestinal Stromal Tumors
por: Brčić, Iva, et al.
Publicado: (2021) -
Diagnostic and treatment strategy for small gastrointestinal stromal tumors
por: Nishida, Toshirou, et al.
Publicado: (2016) -
Clinical activity of regorafenib in PDGFRA-mutated gastrointestinal stromal tumor
por: Grellety, Thomas, et al.
Publicado: (2015) -
Deep learning predicts patients outcome and mutations from digitized histology slides in gastrointestinal stromal tumor
por: Fu, Yu, et al.
Publicado: (2023)